Document is current
Any future updates will be listed below
-
Authors
Lai, Ming-Yu
Wu, Hao-Xiang
He, Ming-Ming
Guan, Wen-Long
Xu, Sheng
Hu, Han
Xu, Ya-Ling
Wang, Feng-Hua
Xu, Rui-Hua
Qiu, Miao-Zhen https://orcid.org/0000-0002-4774-6235
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82102921)
the Guangdong Esophageal Cancer Institute Science and Technology Program (Q202412)
Cancer Innovative Research Program of Sun Yat-sen University Cancer Center (CIRP-SYSUCC-0004)
Sanming Project of Medicine in Shenzen Municipality (SZSM202211017)
the Noncommunicable Chronic Diseases-National Science and Technology Major Project (2024ZD0520600)
the Guangdong Basic and Applied Basic Research Foundation (2024B1515020120)
Young Talents Program of Sun Yat-sen University Cancer Center (YTP-SYSUCC-PT22142001)
- License Information
-
More Information
Article History
Received: 26 April 2026
Accepted: 7 July 2026
First Online: 20 July 2026
Declarations
Ethics approval and consent to participate: Not applicable.
Consent for publication: Not applicable.
Competing interests: Sheng Xu, Han Hu, Ya-Ling Xu are employees of BeOne Medicines. Rui-Hua Xu has served as a consulting or advisory role for Astellas, MSD, AstraZeneca, Junshi, BeOne Medicines, Innovent, CPPC. All other authors declare no financial relationships with any organisations that might have an interest in the submitted work.
